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Severe alpha-1-antitrypsin (AAT) deficiency, phenotype Pi ZZ, is a rare condition with an estimated prevalence of 
114500 individuals in Spain. Given this low prevalence, it seems useful to accumulate all the information derived 
from the care of these patients. In this context, the Spanish Registry of patients with AAT deficiency was founded 
in 1993; its main objectives were to establish guidelines adapted to our country for the treatment and management 
of AAT-deficient patients, offer expert support to physicians all over the country treating these patients, and provide 
technical support on the determination of Pi phenotyping and genotyping of individuals suspected of being 
AAT-deficient. 
From 1993 to January 1998 the number of enrollees increased from 48 to 223, of which 216 were Pi ZZ. 
Seventy-three per cent were male and only 31.5% were never smokers, mean age was 46 years (SD= 13 years) and 
mean FEV, 53% predicted (s~=31%). 83% were index cases who, compared with non-index cases, were older 
(49 i 11 vs. 35 * 13 years, P<O.OOl), more likely to have a smoking history (85% vs. 47%, PcO.01) and displayed 
more severe impairment in pulmonary function (FEVi%=40% + 19% vs. 96% & 23%, P<O.OOl). Augmentation 
therapy was administered to 129 patients (58%). Treated patients had more severe impairment in pulmonary 
function than the untreated (FEV,%=40% & 21% vs. 72% * 32%, P<O.OOl) and were more likely to be index cases 
(81% vs. 43%, PcO.001). 
Characteristics of the patients included are similar to those described for other Registries. The Registry has 
extended knowledge of the disease throughout the country and has established local guidelines for treatment and 
follow-up. It may be a valid database for future co-operation in international initiatives. 
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Introduction 
Hereditary deficiency of alpha-1-antitrypsin (AAT), the 
main serum inhibitor of proteolytic enzymes, is associated 
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with increased risk of pulmonary emphysema of early 
onset, with cigarette smoking being the most important risk 
factor. Although there are more than 70 biochemical gen- 
etic variants of AAT, the most important deficient variant 
is the 2 type. Patients homozygous for the Z allele have 
only lo-20% of the normal serum concentration of the 
inhibitor. 
AAT deficiency is rare. The deficient Z allele is almost 
limited to the white population and is almost inexistent 
among other non-European populations (l-3). Geographi- 
cal differences are also found in the prevalence of the Z 
mutation in the form of a north-south gradient. This 
mutation is more frequent in Scandinavian countries [gene 
0954.6111/98/101181+07 $12.00/O 0 1998 W. B. SAUNDERS COMPANY LTD 
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frequency 0.023 in Sweden (3) and Denmark (4)], than in 
Mediterranean countries [O.OlS in Spain (5)]. With these 
figures, the estimated number of homozygous Pi ZZ 
(phenotype inhibitor) individuals ranges from l/l600 in 
Scandinavia to 114500 in Spain. 
Owing to the low prevalence of AAT deficiency, there is 
a need to accumulate information derived from the study of 
individuals with the disease. In this respect, the Danish 
Registry was founded in 1978 and in 1994 included more 
than 500 individuals (6). However, the greatest interest for 
the registries came with the availability of an augmentation 
treatment for the disease. It was realized early on that a 
clinical trial to ascertain the long-term clinical efficacy of 
such treatment would be unaffordable (7); consequently, 
some registries appeared as an alternative to a clinical 
trial (8,9) by comparing the clinical evolution of a great 
cohort of patients with and without augmentation therapy 
(10,ll). 
The Spanish Registry of patients with AAT deficiency 
was founded in 1993 (12) but because of the relatively small 
expected number of individuals to be recruited, the initial 
purpose of the Registry was not to be an alternative to 
clinical trials on augmentation therapy. The objectives of 
the Registry were: (1) to ascertain the frequency and 
characteristics of AAT deficiency in Spain; (2) to establish 
guidelines adapted to our country for treatment and man- 
agement of AAT-deficient patients; (3) to offer expert 
support to physicians treating these patients all over Spain; 
(4) to increase interest in this rare disease and attempt to 
decrease underdiagnosis and delay in recognition of the 
deficiency; and (5) to offer technical support on the deter- 
mination of Pi phenotyping and genotyping of individuals 
suspected of being AAT-deficient. 
In this report the experience of the first 5 years of the 
Registry is described. 
Methods 
ORGANIZATION OF THE REGISTRY 
The Spanish Registry of patients with alpha-1-antitrypsin 
deficiency (AATD) was founded early in 1993 as a work- 
shop of the IRTS working group (Insuficiencia Respiratoria 
y Trastornos de Sueiio) of the SEPAR (Sociedad Espafiola 
de Neumologia y Cirugia Toracica). Organizational com- 
ponents of the Registry include two co-ordinators (M.M. 
and R.V.), a Steering Committee and 62 participating 
clinical centres, 61 distributed throughout Spain and one in 
Andorra. A Clinical Co-ordinating Center houses the cen- 
tral database of the Registry. In this Centre there is also a 
Central Laboratory (R.J.) which offers support in determin- 
ing Pi phenotype by isoelectric focusing and genotyping via 
DNA extraction and amplification; the techniques used 
have been described extensively in previous works (5,13,14). 
A list of participants in the Registry is provided in the 
Appendix. 
The Steering Committee provides scientific direction for 
the Registry and consists of representatives from some of 
the participating clinical centres and the two co-ordinators. 
An annual conference of representatives from the 
participating clinical centres is held to comment on the 
situation of the database, characteristics of the patients 
enrolled and the specific problems derived from the care 
and treatment of these patients, and the guidelines for 
treatment and follow-up are updated. 
ELIGIBILITY CRITERIA 
To be eligible for inclusion in the Registry, an individual 
must have serum AAT below 35% of normal values 
(<50 mg dl- ’ or < 11 ,UM) and phenotype Pi ZZ or other 
severe deficient variants. For patients receiving augmenta- 
tion therapy, serum AAT levels must have been determined 
before the first dose, or after therapy has been suspended 
for 4 weeks. Patients with phenotype Pi SZ are not included 
in the Registry unless they have serum levels of AAT 
< 11 ,uM and are administered augmentation therapy on the 
decision of the corresponding physician. 
The Registry collects information at 6-month intervals on 
demographic data, medical history, pulmonary function 
measurements which include prebronchodilator and post- 
bronchodilator FEV, and FVC, and information on the use 
and frequency of augmentation therapy as well as the 
possible incidence of adverse side-effects. 
Lung function measurements (spirometry) were per- 
formed in the respective participating clinical centres and 
reported by the referring physician. All participant centres 
performed measurements according to European recom- 
mendations (15). The percentage of the reference values was 
calculated using Mediterranean population reference values 
(16). In this report the postbronchodilator FEV, was used 
in all calculations. 
Family study after the diagnosis of an index case was 
recommended by the Registry, but the Registry itself did 
not perform the investigation, which depended on the 
criteria of each participating centre. 
DATA MANAGEMENT 
Standardized data forms were used to record data at each 
clinical centre. The forms were mailed to the SEPAR office, 
from where they were sent to the Co-ordinating Centre. 
Forms were logged and entered into a microcomputer- 
based data management system. Exploratory analysis to 
detect missing or out-of-range values was performed for 
purging of the database. Characteristics of the patients 
included in the Registry in January 1998 are described in 
the present paper. 
Statistical analysis was performed using the Statistical 
Analysis System software (SAS-Institute, Cary, NC, 
U.S.A.). The Student’s t-test was used for comparisons 
between means and the chi-square test was used to study 
the relationship between categoric variables. A difference of 
PcO.05 was considered significant. 
Results 
Two hundred and twenty-three individuals had been 
included in the Registry from 1993, of whom four died 
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FIG. 1. Cumulative number of enrollees in the Registry 
over time. 
during follow-up and four received a lung transplant. Pi 
phenotypes were: 216 Pi ZZ, two Pi SZ, three Pi 
ZMmalton, two Pi ZMpalermo. The cumulative number of 
enrollees over time is shown in Fig. 1. 
Geographical distribution of the individuals included is 
uneven with a greater number of individuals belonging to 
the regions of Northern Spain compared with the centre 
and the South. Case density in the different autonomous 
communities of Spain is depicted in Fig. 2. Three commu- 
nities have not reported any case to the Registry: Murcia, 
La Rioja and the Balearic Islands. 
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Demographic, clinical and functional characteristics of 
enrollees are shown in Table 1. There is a predominance of 
men (73%) ex-smokers (62.5%) and individuals included 
because of pulmonary symptoms (83%), while those 
diagnosed by family screening represent 14%. 
Comparison between index cases, i.e. those identified 
through chest symptoms, and non-index cases is shown in 
Table 2. 
Criteria established by the Registry to initiate augmenta- 
tion therapy with intravenous AAT (Prolastina@; Bayer 
Pharmaceutical; West Haven, CT, U.S.A.) are depicted in 
Table 3. Decisions to treat with augmentation therapy were 
always left to the discretion of the enrollees’ attending 
physicians. Frequency and dosage of augmentation therapy 
recommended by the Registry was 180 mg kg- ’ every 3 
weeks. A total of 129 (58%) patients were receiving aug- 
mentation therapy at the time of enrolment or initiated the 
treatment the year after enrolment; their characteristics and 
comparison with those not receiving augmentation therapy 
are shown in Table 4. Administration frequency of augmen- 
tation therapy was: weekly four patients (3%), every 2 
weeks 16 (12%), every 3 weeks 99 (77%), monthly 3 (2.3%) 
and not stated seven (54%). Regarding functional impair- 
ment, 65% (84/129) of patients with FEV,<30% were 
receiving augmentation therapy, 67% (29143) of those with 
FEV, between 30% and 49%, 65% (1107) of those with 
FEV, between 50% and 69%, and 15% (5/34) of those 
with FEV, 2 70%. 
Of the four patients who died, three had an FEV,<30% 
predicted; two of these died of pulmonary emphysema and 
the other of acute peritonitis due to diverticulitis. The 
remaining patient had an FEV, of 60% predicted and died 
of disseminated stomach cancer. 
FIG. 2. Case density of alpha-I-antitrypsin deficient individuals in the different autonomous communitie :s of Spain. 
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TABLE 1. Demographic, clinical and functional characteris- 
tics of individuals with AAT deficiency at enrolment 
n % Mean (SD) 
Male gender 
Age (years) 
Age at onset (years) 
Ascertainment* 
163 73 
46 (13) 
39 (10) 
Lung disease 
Family 
Other 
Smoking statust 
145 83 
25 14 
5 3 
Never 42 31.5 
Ex 83 62.5 
Current 8 6 
Augmentation therapy 129 58 
FEV, (ml) 1726 (1200) 
FEV, (% predicted) 53 (31) 
*Percentages refer to 175 enrollees for whom this 
information is available. 
TPercentages refer to 133 enrollees for whom this 
information is available. 
Discussion 
Since its foundation in 1993, the Spanish Registry has 
included a total of 223 patients, of whom four have died 
and four received a lung transplant up to January 
1998. Most of the enrollees are males in the fourth or fifth 
decade of life with a history of cigarette smoking and 
pulmonary symptoms and lung function tests consistent 
with emphysema. More than one half of the enrollees 
are receiving augmentation therapy, with the patients 
treated being older, more likely to have smoked and with 
severe pulmonary function impairment with a mean FEV, 
TABLE 3. Criteria for augmentation therapy established by 
the Spanish Registry of patients with alpha-1-antitrypsin 
deficiency 
1. Evidence of pulmonary emphysema 
2. Serum levels of AAT<35% reference values 
3. FEV,<70% predicted 
Patients with FEV,>SO% should demonstrate a 
decline in FEV, > 150 ml yr - ’ 
4. Age > 18 years 
5. Non-smokers at least for 1 year 
6. No other important co-morbid conditions 
7. Ability to attend the corresponding clinical centre 
of only 40% predicted. Only 17% of cases have been 
diagnosed despite not having respiratory symptoms (non- 
index cases) and the majority were identified through 
family screening of an index case. This description is similar 
to that of the NHLBI Registry in the U.S.A. (10) where 
non-index cases represent 28% of enrollees, but clearly 
below the Danish Registry where cases diagnosed 
through family screening constitute almost one half of the 
enrollees (6). 
A recent study in Barcelona observed a gene frequency of 
the Z allele to be 0.015 (5). If this frequency were valid for 
the whole country, the expected number of individuals 
homozygous for Pi ZZ in Spain would be approximately 
8400. The number of patients registered is 0.58/100 000, 
ranging from 0 in three regions or 0.08/100 000 in Valencia 
to 31100 000 in Cantabria and Asturias, and represents 
globally 2.6% of the total deficient individuals expected. 
This percentage lies between that of the NHLBI Registry 
(10) and other Registries with a longer tradition such as the 
Danish one, where approximately 28% of the estimated 
number of patients in the 30-59 year age category are 
registered (6). 
TABLE 2. Comparison between index and non-index cases 
Index Non-index 
n= 145 n=30 P 
Men (%) 
Death (%) 
Lung transplant (%) 
Non-smokers (%) 
Pack-year 
(smokers and ex-smokers) 
Age (years) 
Augmentation 
therapy (%) 
FEV, (ml) 
FEV, (%) 
Values are mean & SD. 
*Chi-square test. 
TStudent’st-test. 
78 60 0.21” 
3 0 n.s.* 
3 0 n.s.* 
15 53 cO.Ol* 
29* 17 16& 13 10.05? 
49& 11 35 zt 13 <o.o01t 
78 16 ~o~ool* 
1242 =t 699 3358 zt 1252 <O.OOl~ 
40* 19 96 rt 23 <o.o01t 
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TABLE 4. Comparison between patients receiving and not 
receiving augmentation therapy 
Treated Untreated 
n=131 n=92 P 
Men (%) 74 
Age (%) 48+ 10 
Death (“Yo) 2 
Lung transplant (%) 3 
Index cases (%) 81 
Non-smokers (%) 9 
FEV, (ml) 1210 + 633 
FEV, (%) 40&21 
70 0.60” 
42f 16 <O.OlT 
2 n.s.* 
0 n.s.* 
43 ~o~ool* 
31 co.o01* 
2458 zt 1428 <O.OOlt 
72 xt 32 <O.OOlT 
Values are mean & SD. 
*Chi-square test. 
TStudent’s t-test. 
The differences observed in some regions are not likely to 
be due to differences in gene frequencies (5,17,18) or 
cigarette smoking habits, but to differences in diagnostic 
rates due to the existence or not of medical groups inter- 
ested in the deficiency in different areas. It is well docu- 
mented that some non-smoking, non-index deficient 
individuals will never develop significant emphysema and 
thus will not be detected (6,19,20), but even today many 
patients with early onset emphysema due to the deficiency 
are misdiagnosed for many years as having smoking-related 
disease, until the final diagnosis of the deficiency is (if ever) 
established. In a national series, mean delay in diagnosis 
was 10 years (range=3-22 yr) although mean age at 
diagnosis was only 46 yr and mean FEV, 0.80 1 (21). 
The criteria established by the Registry for initiating 
augmentation therapy are very restrictive. Patients must 
refrain from smoking for at least 1 year and present 
pulmonary function impairment consistent with emphy- 
sema; those with FEV, >50% predicted must show an 
annual decline of more than 150 ml. The reasons for 
adopting these restrictive criteria are lack of definitive 
evidence of the clinical efficacy of the therapy, and lack of 
information on which patients are going to benefit more 
from the treatment, together with the fact that the treat- 
ment is very expensive and of limited availability (22) and 
its use should be, in our opinion, restricted to patients with 
well-defined characteristics in the setting of experimental 
trials or under the supervision of national or international 
registries. Nevertheless, the decision to treat is left to the 
corresponding physicians and in our series, at least five 
patients on augmentation therapy did not fulfil all criteria 
and, conversely, eight patients who did meet the criteria 
were not receiving augmentation therapy for different 
reasons, including the limited availability of the product. 
Most of the patients on augmentation therapy were 
receiving AAT on an every-3-weeks schedule following the 
recommendations of the Registry. This dosage was adopted 
because in Spain almost all patients are treated in a 
hospital-based administration programme, some are still 
employed, and others depend on their relatives to attend 
the hospital. For these reasons, the weekly or even every- 
2-weeks schedules are difficult to accept for most patients. 
The biochemical efficacy of augmentation therapy in terms 
of obtaining serum AAT levels above those considered 
protective (80 mg dl - I or 11 pM) and enhanced antineu- 
trophil elastase activity in both serum and BAL fluid 
throughout the period between doses has only been proven 
for the weekly administration (23,24). The efficacy of other 
administration regimens is under debate; some authors 
have found good serum AAT levels with a 2 weeks’ interval 
(25) while others suggest that this interval is too long (26). 
Hubbard et al. (27) reported that after a single infusion of 
250mg kg-’ of AAT, serum levels remained above 
80 mg dl- i for approximately 21 days. Considering the 
pharmacokinetics of the infused AAT, with a rapid decline 
in serum levels during the first 2 days and a slower phase of 
elimination proportional to the serum concentration, it 
seemed more reasonable to reduce the interval between 
infusions than to increase the total dose. Consequently, the 
Registry recommended a dose of 180 mg kg - i every 
3 weeks, a regimen already reported in another recent 
study (28). 
Two considerations must be made at this point: first, we 
are only considering biochemical efficacy, and although 
some promising data exist on the clinical efficacy of the 
treatment (8,11,21,28-30) definitive evidence is lacking. 
Furthermore, it is not known to what extent the fact that 
serum AAT levels are below 80 mg dl - i during the last few 
days of each cycle of treatment implies a worse outcome of 
therapy; second, the approach of a standard dose for every 
patient may be too simple: patients with purulent bronchi- 
ectasis or frequent infectious exacerbations may need 
higher doses of AAT to compensate for the higher neu- 
trophil elastase burden (31). Consequently, a trough serum 
AAT level of 50 mg dl - ’ may be sufficient for an asymp- 
tomatic patient (in fact, some Pi ZZ non-smokers do not 
develop significant emphysema), while a concentration of 
120 mg dl - ’ might be insufficient for a patient suffering 
from recurrent acute infectious exacerbations (3 1,32). 
Since the beginning in 1993, the number of enrollees has 
increased from 48 to 223. They come from almost all the 
communities in Spain, which demonstrates a more extended 
awareness of this condition. The Registry has established 
local guidelines for augmentation therapy and follow-up of 
patients with the deficiency and has contributed to the 
rational utilization of a product of limited availability and 
high cost. Furthermore, the Registry has offered physicians 
interested in this rare condition the opportunity to meet and 
work together for better understanding of the disease, 
and should be a valid platform for co-operation with 
international initiatives. 
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Baracaldo (Vizcaya): B. Galdiz; Barcelona: R. Vidal, M. 
Miravitlles, A. Torres, R. Jardi; CLEceues: A. Sojo; Chdiz: C. 
Garcia; Cartagena (Murcia): P. Belindres; Ferrol (La 
ComAa): R. de 10s Reyes; Galdakao (Vizcaya): P. Espaiia; 
Getafe (Madrid): M. A. Juretschke; Gij& (Asturias): T. 
Bazus; Girona: M. Rubio; Granada: F. Casas; Guadalajara: 
J. L. Izquierdo; Hondarribia (San Sebasticin): J. F. 
Capellan; Huelva: F. Barragan; La Corufia: C. Montero; 
Leganb (Madrid): M. Yoldi; Lugo: L. A. Perez; Madrid: L. 
Maiz, J. Jarefio, F. Villegas, M. J. Chillon, L. Sanchez- 
Agudo, M. Martinez, B. Ortega, J. Gaudo, J. Lirio, G. 
Marin, F. Artalejo, M.C. Rodriguez de Guzman, J. M. 
Carreras; Mhlaga: J. J. Martin, F. Espildora; Orense: A. 
Rodriguez, A. Gonzalez; Oviedo: J. Palicio, C. Escudero; 
Pamplona: F. J. Dominguez, J. Boldu; Ponferrada (La 
Coruria): S. Fernandez; Pontevedra: A. Baloira, A. Pena; 
Puertollano (Ciudad Real): W. El Jawat; Riafio-Langreo 
(Asturias): I. Blanco; Sabadell (Barcelona): J. Such; Sala- 
manca: J. M. Gonzalez; Santander: R. Agiiero; Santiago 
(La Corufia): R. Arias, L. Valdes; Santa Cruz de Tenerife: 
I. Garcia; San Sebastih: P. de la Torre; Tarragona: J. 
Aguilar; Tenerife: Gonzalez Abreu; Teruel: J. A. Domingo; 
Torrelavega (Santander): A. Bustamante; Tremp (Lleida): 
J. Alvarez; Trevias (Asturias): J. E. Armengod; Valencia: 
V. Crescencio, J. France, G. Juan; Valladolid: A. Herrero; 
Vigo: J. C. Barros-Tizon, J. M. Barreiro, R. Band&, M. 
Jimenez; Vitoria: J. L. Lobo, M. Perez; Zaragoza: I. 
Herrero, C. Aguirre. 
